CCR7 and neoplasm: Recent studies have shown that CD39−CD69− T cells have TSCM properties in tumor-infiltrating lymphocyte therapy (40), and Galletti and colleagues (38) classified CCR7+ cells of CD8+ T cells in peripheral blood as follows: